mRNA technology — proven at unprecedented scale through COVID-19 vaccines — is being repurposed across oncology, rare disease, infectious disease, and autoimmune indications. Personalized cancer vaccines using mRNA — generating a unique therapeutic for each patient based on their tumor's mutational profile — are in Phase 3 trials at Moderna and BioNTech in partnership with Merck. mRNA-based protein replacement therapies for rare metabolic diseases are in clinical development. The technology's ability to encode virtually any protein makes it theoretically applicable to hundreds of disease indications where existing small molecule and biologic approaches have failed.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• mRNA Technology Platform
• Personalized Cancer Vaccines
• mRNA Rare Disease Therapies
• Respiratory Vaccine Pipeline
• mRNA Autoimmune Programs
• Moderna and BioNTech Platform Comparison
• Lipid Nanoparticle Delivery
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. mRNA Technology Platform
4. Personalized Cancer Vaccines
5. mRNA Rare Disease Therapies
6. Respiratory Vaccine Pipeline
7. mRNA Autoimmune Programs
8. Moderna and BioNTech Platform Comparison
9. Lipid Nanoparticle Delivery
10. Competitive Landscape
11. Competitive Landscape
12. Regional Market Analysis
13. Strategic Conclusions and Recommendations
14. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Pipeline Assessment 2025
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Pfizer
Novartis
Johnson & Johnson
Daiichi Sankyo
Seagen
AbbVie
